Inovio Pharma (INO) Says Presentation at ASCO Show Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
Tweet Send to a Friend
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced a poster presentation of additional prostate cancer data (Abstract #229675) at the American ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
